Houston startup's AI-driven networking and education platform to soft launch in TMC

going online

Flourishing Nexus recently won runner up in the innovation category of the city's Liftoff Houston competition. Photo courtesy of the City of Houston

Connecting medical professionals is about to get easier thanks to a new Houston company, Flourishing Nexus.

Next month, their digital platform, The Nexus, will debut to in a soft launch to a curated group of TMC employees.

“Think of it as a combination of existing platforms like LinkedIn, providing professional networking; Khan Academy, which provides excellent training and education; and a collaborative workspace like Google Workspace or Microsoft Teams, all enhanced by AI,” says Diane Nguyen.

Nguyen is a pharmacist by training, while her co-founder, Satid Thammasitboon, is an MD and master in health professions education.

The pair began working together in the health professions education space three years ago, but only established Flourishing Nexus in July of 2023. The company’s moniker refers to the concept of human flourishing.

“Our mission would be to promote human flourishing among health professionals,” says Thammasitboon.

The concept of human flourishing traces back at least to Aristotle, but The Nexus’ understanding of it is based on psychologist and educator Martin Seligman’s PERMA theory. The mnemonic stands for Positive Emotion, Engagement, Relationships, Meaning, and Accomplishment.

“We endeavor to bring these concepts of PERMA and human flourishing into the health professions space,” says Nguyen.

“Often our healthcare organizations or industries, when they hear health professionals are having issues with burnout, the response or reaction would be to increase incentive, financial support, or professional development to enhance resilience,” adds Thammasitboon. “We search for meaning we want to make a difference in the life of another rather than ‘everything is all about money.’”

Both professionals have globe-spanning careers. Thailand native Thammasitboon says that his endeavors have taken him across Europe, Southeast Asia, and East Asia, while Nguyen’s work has focused her attention on South America, sub-Saharan Africa, and Eastern Europe.

“I realized that the key to providing better outcomes and health care for the patients was really dependent on the continuing education and training of the staff,” Nguyen says.

Those experiences proved to be the roots from which The Nexus grew.

But the team’s colleagues abroad won’t be among the first The Nexus users. That distinction will belong to Houston’s rich community of medical pros. And when the platform soft launches in January, it will be with two awards already under its belt.

The Liftoff Houston Startup Business Plan competition took place last month. Nine finalists, mostly entrepreneurs from underrepresented backgrounds, were selected from among 100 applicants to compete in Liftoff’s Pitch Day. Not only was The Nexus among those competitors, it raked in a runner-up prize, as well as fan favorite in the innovation category.

Nguyen, who did the pitching, says that Liftoff helped Flourishing Nexus tremendously with both its preparation workshops and feedback from the judges.

“Sometimes you think you have a great idea but it’s not until you critically think about your own plan, analyze your plan, and prepare to pitch it that you really learn about it. This preparation helped us and strengthened our mission. Our business plan is much better,” says Thammasitboon.

Next up? Launching and growing The Nexus’ community. Nguyen also says they plan to participate in more competitions, including possibly Houston Community College’s Business Plan Competition. It’s one more way of bringing the abstract concept of human flourishing to a flesh and blood audience.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME